InMode Ltd. (NASDAQ:INMD) Position Reduced by Nemes Rush Group LLC

Nemes Rush Group LLC trimmed its holdings in InMode Ltd. (NASDAQ:INMD) by 40.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,029 shares of the healthcare company’s stock after selling 1,378 shares during the quarter. Nemes Rush Group LLC’s holdings in InMode were worth $45,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in INMD. Aigen Investment Management LP boosted its holdings in shares of InMode by 22.9% in the fourth quarter. Aigen Investment Management LP now owns 12,572 shares of the healthcare company’s stock worth $280,000 after buying an additional 2,341 shares during the period. Trexquant Investment LP acquired a new position in shares of InMode during the fourth quarter worth approximately $826,000. D.A. Davidson & CO. boosted its holdings in InMode by 8.1% in the 4th quarter. D.A. Davidson & CO. now owns 31,405 shares of the healthcare company’s stock valued at $698,000 after purchasing an additional 2,360 shares during the period. Norges Bank bought a new position in shares of InMode during the 4th quarter worth about $8,890,000. Finally, First National Advisers LLC raised its position in shares of InMode by 26.8% during the fourth quarter. First National Advisers LLC now owns 26,343 shares of the healthcare company’s stock valued at $586,000 after buying an additional 5,566 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors.

InMode Price Performance

Shares of INMD stock traded up $0.28 during trading hours on Wednesday, hitting $19.03. 417,763 shares of the company’s stock were exchanged, compared to its average volume of 1,493,033. The stock’s 50-day moving average is $19.04 and its 200-day moving average is $21.24. InMode Ltd. has a 52 week low of $16.72 and a 52 week high of $48.25. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of 8.91 and a beta of 2.20.

Analyst Upgrades and Downgrades

INMD has been the topic of a number of research reports. UBS Group boosted their price objective on InMode from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, February 14th. Barclays reduced their price objective on shares of InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, April 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of InMode in a research note on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, InMode presently has an average rating of “Hold” and an average target price of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.